Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study

Table 1

Inclusion criteria (patients were eligible if all of the following applied)
(1) Classified MS diagnosis
(2) Written informed consent has been obtained
(3) Patients are willing and able to complete the micturition diary correctly
(4) Complaints of OAB
(a) Urgency/Frequency (micturition frequency > 8/day)
(b) Urge incontinence (involuntary loss of urine after a sensation of urge)
Exclusion criteria (patients would be excluded from participation if any of the following apply)
(1) Significant postvoid residual volume (PVR >200 mL)
(2) Evidence of a urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy, or previous or current malignant disease of the pelvic organs
(3) Uncontrolled narrow angle glaucoma, urinary or gastric retention, or any other medical condition which in the opinion of the investigator makes the use of anticholinergics contra-indicated
(4) Non-drug treatment including electrostimulation therapy or start of a bladder training program during the 12 weeks prior to or during the study
(5) Use of drugs intended to treat urinary incontinence
(6) Known or suspected hypersensitivity to other anticholinergics or lactose
(7) Any clinical significant condition, which in the opinion of the investigator makes the patient unsuitable for the trial
(8) Pregnancy or the wish to become pregnant during the study